Compiled 2026-09-26Data through 2025-04-252 min read
Dated source-based research · No live market data

Observation

Across 15 eligible healthcare companies, the equal-weight median revenue growth was 8.67% for the prior selected annual periods.

Data context

The eligible sample covers 15 of 16 selected companies. The prior selected annual periods span 2024-12-29 to 2025-04-25. Companies have different fiscal year ends. This is a cross-sectional research sample, not a calendar-year index or a representation of the full sector.

Company evidence

LLY 32.00% (period 2024-12-31); JNJ 4.30% (period 2024-12-29); ABBV 3.71% (period 2024-12-31); MRK 6.74% (period 2024-12-31); AZN 18.04% (period 2024-12-31); AMGN 18.57% (period 2024-12-31); GILD 6.04% (period 2024-12-31); ABT 4.59% (period 2024-12-31); PFE 24.97% (period 2024-12-31); ISRG 17.24% (period 2024-12-31); VRTX 11.66% (period 2024-12-31); BMY 7.32% (period 2024-12-31); MDT 3.62% (period 2025-04-25); SYK 10.23% (period 2024-12-31); HCA 8.67% (period 2024-12-31).

Distribution

The sample range is 3.62% (MDT) to 32.00% (LLY). The median is computed across company ratios with equal weight; it is not a ratio of aggregate totals. Extreme values can reflect a small denominator or unusual accounting items.

Interpretation

Drug developers, device manufacturers and care providers depend on distinct clinical, reimbursement and operating economics. Revenue growth uses the next older annual observation as its denominator; only positive base revenue qualifies. No missing value is replaced with zero.

What to watch

Product concentration, research investment, utilization, reimbursement and cash generation.

Research limitations

Patent expiry, trial outcomes, reimbursement changes, litigation and acquisition integration. The sample uses a September 18, 2026 source snapshot. It does not establish current market conditions, causal drivers or future returns. Sector labels are editorial and the financial-sector cash-flow measures need particular caution.

Company-level observations · percent
CompanyValuePeriod end
LLY32.00%2024-12-31
JNJ4.30%2024-12-29
ABBV3.71%2024-12-31
MRK6.74%2024-12-31
AZN18.04%2024-12-31
AMGN18.57%2024-12-31
GILD6.04%2024-12-31
ABT4.59%2024-12-31
PFE24.97%2024-12-31
ISRG17.24%2024-12-31
VRTX11.66%2024-12-31
BMY7.32%2024-12-31
MDT3.62%2025-04-25
SYK10.23%2024-12-31
HCA8.67%2024-12-31

Sources & dates